Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07173543 · ClinicalTrials.gov registry record · NA
IH, Brain Health, and T2D
A NA study of Type 2 Diabetes and Aging, sponsored by Darren P Casey.
- Recruiting
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT07173543: Recruiting NA study of Type 2 Diabetes and Aging, sponsored by Darren P Casey.
NCT07173543 is a NA study of Type 2 Diabetes and Aging that is actively recruiting participants, run by Darren P Casey. The registered enrollment target is 80 participants, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07173543, a NA study of Type 2 Diabetes and Aging, is actively recruiting participants, sponsored by Darren P Casey.
- RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to use a randomized, placebo-controlled study design to rigorously examine the therapeutic potential of intermittent hypoxia (IH) for improving cerebrovascular health in older adults with and without type 2 diabetes mellitus (T2DM).
Primary Outcome
ICA dilation (% change) will be determined using Doppler ultrasound in response to acute hypercapnia.
Conditions Studied
Interventions
- OTHER Intermittent Hypoxia 1 (IH1)
- OTHER Intermittent Hypoxia 2 (IH2)
- OTHER SHAM - normoxia
Study Locations (1)
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-09-22 |
| Est. Completion | 2028-06-30 |
| Phase | NA |
What NCT07173543 shows while recruiting
NCT07173543 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 3 interventions - of which Intermittent Hypoxia 1 (IH1) is the first listed.
NCT07173543 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT07173543 about?
NCT07173543 is a clinical study titled "IH, Brain Health, and T2D". The purpose of this study is to use a randomized, placebo-controlled study design to rigorously examine the therapeutic potential of intermittent hypoxia (IH) for improving cerebrovascular health in older adults with and without type 2 diabetes mellitus (T2DM).
What is the current status of trial NCT07173543?
This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2025-09-22. Estimated completion is 2028-06-30.
What conditions does trial NCT07173543 study?
This clinical trial studies the following conditions: Type 2 Diabetes, Aging.
What interventions are being tested in trial NCT07173543?
The interventions under investigation include: Intermittent Hypoxia 1 (IH1) (OTHER), Intermittent Hypoxia 2 (IH2) (OTHER), SHAM - normoxia (OTHER).
Who is sponsoring clinical trial NCT07173543?
This trial is sponsored by Darren P Casey, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07173543 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07173543's enrollment target sits among peer trials
80 175th of 327 higher than 150 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhancing Telemedicine for T2D
RECRUITING · NA
-
Sleep and Glycemic Control in Type 2 Diabetes Adolescents
RECRUITING · NA
-
Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients
RECRUITING · NA
-
Ultrasound Effects on Glycemic Control in T2DM
RECRUITING · NA
-
A Randomized Double-Blinded and Placebo-Controlled Trial to Assess the Efficacy of Biophoton Therapy to Treat Type 2 Diabetes
RECRUITING · NA
-
High Fructose Diet, the Gut Microbiome, and Metabolic Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI